Talactoferrin
Phase 3Small molecule
Talactoferrin is one of 43 small molecule programs targeting Nosocomial Infection. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Talactoferrin
AAgennix
Phase 3
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
REGN2810
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Talactoferrin. EMBL-EBI & Wellcome Sanger Institute.
- [4]